Meeting
2021 Genitourinary Cancers Symposium
Real-world comparison of abiraterone (A) versus enzalutamide (E) for first-line therapy of metastatic castration-resistant prostate cancer (mCRPC).
Authors
Juan Rodrigo Briones Carvajal
Odette Cancer Centre, Toronto, ON, Canada
Juan Rodrigo Briones Carvajal , Mahdi Farzad Naimi , Liying Zhang , Urban Emmenegger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session: Prostate Cancer - Advanced Disease
Track
Prostate Cancer - Advanced
Sub Track
Therapeutics
Citation
J Clin Oncol 39, 2021 (suppl 6; abstr 133)
DOI
10.1200/JCO.2021.39.6_suppl.133
Abstract #
133
Poster Bd #
Online Only
Abstract Disclosures
Similar Posters
Poster
2018 Genitourinary Cancers Symposium
Effect of germline DNA repair gene mutations on outcomes in men with metastatic castration-resistant prostate cancer receiving first-line abiraterone and enzalutamide.
First Author: Emmanuel S. Antonarakis
First Author: Elena Castro
Poster
2024 ASCO Genitourinary Cancers Symposium
The survival outcomes for men with metastatic castration-resistant prostate cancer (mCRPC) with and without homologous recombination deficiencies (HRD) treated with radium-223: Princess Margaret Cancer Centre (PMCC) experience.
First Author: Esmail M. Al-Ezzi
Poster
2023 ASCO Genitourinary Cancers Symposium
![Efficacy of systemic therapy following [<sup>177</sup>Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).](https://d201v5jt9ylckg.cloudfront.net/298/15164/217588/217588_A228_poster_pv.jpg)
Efficacy of systemic therapy following [177Lu] Lu-PSMA in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).
First Author: Louise Kathleen Kostos